
Taking a mitochondria drug into the clinic for Parkinson's at @VincereBio. AI + biology for more healthy years. I post pharma deal data and longevity science.
Boston, MA
Joined February 2011
- Tweets5.9K
- Following743
- Followers1.3K
- Likes9.8K
Pinned Tweet
What if the most important thing we build with technology isn't AI, but more time? More healthy years to live, love, explore, and create. I shared this vision at TEDxBoston. Sharing the whole story here for you.
I've spent 40+ years asking computers to do harder and harder things. Now we're asking them to help solve one of humanity's oldest problems: why do our bodies decline with age, and what can we do about it?
My wife Spring is a neuroscientist. Together, we saw three things converging: computing power once reserved for supercomputers, mountains of human biological data, and AI capable of finding patterns no human could hold in mind.
Then we encountered the two-headed beast of Biology data. One head everything we know - millions of papers, conflicting results, incomplete models. The other everything we don't know.
No human could read the millions of papers on Parkinson's and neurodegeneration. So we built gathered and cleaned all the data. Built first of their kind models.
One answer kept rising to the top: the mitochondria were failing. Not just energy production, maintenance. Our cells recycle damaged mitochondria through mitophagy, and that process declines with age. In Parkinson's, it's really broken. The relationship to aging is reciprocal: In fruit flies, enhancing mitophagy extended lifespan by 28%.
Our models pointed to an unlikely target to get the job done: USP30, a parking brake on mitochondrial recycling. At the time, only about 20 papers even mentioned it. We started building molecules to release the brake. 723 iterations later, we had a potent, selective USP30 inhibitor. In aged mice, it produces a sixfold increase in mitophagy in the brain cells most vulnerable in Parkinson's. Promising preclinical results, but not yet proof in humans.
We've now completed the final preclinical safety studies, with human trials on deck. And a new challenge awaits: measuring what's happening inside living human brains. Millions of indirect signals, changing over time; another problem where AI may help us see what wasn’t possible before.
The tools will keep changing. What matters is choosing a why worth solving. For me, it's more time to dance with my wife. More time around crowded tables with family and friends. More time to turn ideas into reality.
A future with more time won't just happen.
We will build it.
Full 9-minute talk: youtu.be/qiVvIJTP6T8
#Parkinsons #longevity #TEDx
1
2
297
European pharma companies licensed more assets from China than from Europe.
I'm in London for Life Sciences Week, and that finding keeps coming up in conversations. 175 public deals, 2022 through mid-2026. You're not just competing with the company down the street.
Source: 175 public licensing and option deals, January 2022–June 2026. Acquisitions excluded.
US-headquartered companies were the largest buyer group from all three sources: the US, China, and Europe. Companies headquartered in the EU, UK, and Switzerland collectively licensed more Chinese assets than European ones.
Deals measure appetite. Clinical outcomes measure whether that appetite was justified.
32
We all want more time - some of us are building it.
Looking forward to sharing ideas at tonight's Longevity Exchange during London Life Sciences Week hosted by @LongGameVC @AdBiopartners @athena_dao @LonLongevity and Empirical Ventures.
Who else is going? Come find me.
5
177
OMFG building things with agents is really fun.
Like, yeah, I have a day job talking to people, but the agents get it, do it, and don’t sleep.
Now the interesting puzzle - how to map a swarm of SI to clear the next bottleneck.
Again
And again
And again.
1
3
137
Everything I Needed to Know About VCs, I Learned From My Kittens.
A few weeks ago, we adopted two kittens, Mina and Minoo.
They're beautiful, intelligent, affectionate, easily distracted, and prone to sudden acts of violence.
After years of raising venture capital, the behavior is strangely familiar.
A few observations:
1. Never chase them.
If they back away, turn around. Chasing only makes them run faster.
2. Shiny objects are irresistible.
A new data point. A big partnership. A prestigious name. Suddenly they're all over you. Until they catch it.
3. Emotions change without warning.
One minute they're purring in your lap. The next they're clawing your eyes out. Five seconds later, they're confused about why you're bleeding.
4. Curiosity is not commitment.
They'll sniff, investigate, and bat something around for hours. Then walk away without explanation.
5. They want what the other kitten has.
Neither cares about the toy until one picks it up. Now it's the most valuable object in the universe.
6. They operate on their own schedule.
Ignore you all afternoon. Demand your undivided attention at 3 a.m.
7. The box beats the contents.
Never underestimate the importance of packaging.
8. Personal boundaries are one-sided.
They'll walk across your keyboard mid-call. Try interrupting them, though...
9. Affection is not alignment.
They can love you, admire what you've built, and enjoy spending time together. Doesn't mean they'll do what you want.
10. Stop trying to get them into your lap.
Make yourself comfortable. Be patient. Eventually they'll come to you; usually when you have something else to do.
After considerable observation, I find the principles of kitten management and venture fundraising seem remarkably similar: Build something interesting. Generate competition. Don't appear desperate. Never confuse a warm reception with a commitment.
And yet, I willingly share my home with cats and my business with investors. In both cases, the rewards far outweigh the scratches.
There is one important difference.
The best investors bring more than capital: experience, relationships, judgment, and a shared commitment to building something meaningful.
The best cats mostly help rebalance cortisol and oxytocin. And knock things off your desk.
1
81
25 years ago Spring and I got lost hiking in Muir Woods.
We both had strong ideas on which way to go. We also had one heavy backpack.
So we came up with a simple rule: Whoever carries the backpack gets to make the decisions.
It's worked in marriage and business.
We succeed or fail together, and indecision is death.
When the leader gets tired or unsure, we hand off the backpack.
When two founders call themselves co-CEOs, it doesn’t mean they’ve found a better structure. It means they haven’t decided which one of them is CEO.
1
2
131
I closed my TEDxBoston talk with the most personal part of the whole story.
The tools will keep changing. They'll become more powerful and easier for everyone to use.
What matters is choosing a why worth solving.
For me, it's more time to dance with my wife. More time around crowded tables with family and friends. More time to turn ideas into reality.
That's what we're building toward at Vincere Biosciences — molecules that restore the cellular maintenance system behind Parkinson's and aging, now approaching human trials.
A future with more time won't just happen. We will build it.
Full talk: youtu.be/qiVvIJTP6T8
#Longevity #Parkinsons #TEDx #Mitochondria
USP30 is like a parking brake that holds back mitophagy, the recycling process that clears out damaged mitochondria.
As that recycling slows with age, the damage piles up. In Parkinson's, it's really broken.
@VincereBio is building molecules to release the brake.
From my @TEDxBoston talk. Full talk: youtu.be/qiVvIJTP6T8
1
1
90
What if the most important thing we build with technology isn't artificial intelligence, but more time?
More healthy years to live, love, explore, and create.
I recently had the chance to share this vision at TEDxBoston. Here's the story. 🧵
1
144
Our team has now completed the final preclinical safety studies, with human trials approaching.
And a new challenge awaits: measuring what's happening inside living human brains without directly observing it.
Millions of indirect signals, changing over time.
Another problem where AI may help us see what we couldn't before.
1
24
The tools will keep changing. They'll become more powerful and easier for everyone to use.
What matters is choosing a why worth solving.
For me, it's more time to dance with my wife. More time around crowded tables with family and friends. More time to turn ideas into reality.
This future will take all of us.
A future with more time won't just happen. We will build it.
30





